<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01635855</url>
  </required_header>
  <id_info>
    <org_study_id>P110637</org_study_id>
    <nct_id>NCT01635855</nct_id>
  </id_info>
  <brief_title>Belotero Post Approval Study</brief_title>
  <official_title>Belotero® Post Approval Study for the Treatment of Nasolabial Folds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merz North America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merz North America, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, open-label 1-month post-approval study to evaluate the short term safety of
      Belotero® Balance in the re-treatment of nasolabial folds.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Severe Common Adverse Events</measure>
    <time_frame>1 month</time_frame>
    <description>The purpose of this study was to determine if the rate of &quot;Severe&quot; common adverse events after re-treatment with Belotero Balance differs from the combined rates reported in the Belotero® Balance IDE clinical trial and Belotero® Balance Fitzpatrick Skin Type IV-VI Study (Pre-Approval Studies).&quot;Common&quot; is defined as pre-specified adverse events occurring in &gt;= 5% of study subjects. These averse events are: bruising, itching, pain, redness, swelling, discoloration, nodule, and induration.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">117</enrollment>
  <condition>Nasolabial Folds</condition>
  <arm_group>
    <arm_group_label>Belotero</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Belotero® Hyaluronic acid dermal filler</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Belotero®</intervention_name>
    <description>Hyaluronic acid dermal filler</description>
    <arm_group_label>Belotero</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Was a participant in the Belotero® Balance pre-market IDE clinical trial or the
             Belotero Balance Fitzpatrick Skin Type IV-VI Study.

          2. Is a candidate for bilateral nasolabial fold re-treatment with Belotero® Balance.

          3. Understands and accepts the obligation not to receive any other facial procedures from
             enrollment through 1 month from optimal correction in the current study.

          4. Understands and accepts the obligation to comply with the required follow-up visits
             and is logistically able to meet all study requirements.

        Exclusion Criteria:

          1. Has received surgery in either nasolabial fold.

          2. Has received within the past 6 months a non-permanent filler (e.g. hyaluronic acid,
             CaHA) or neurotoxin below the zygomatic arch.

          3. Has received at any time a permanent filler (e.g. polylactic acid, PMMA, silicone)
             below the zygomatic arch.

          4. Has received within the past 6 months dermal resurfacing procedures (e.g. medium/deep
             chemical peel, dermabrasion treatments, ablative laser resurfacing) or non-invasive
             skin-tightening (e.g. Thermage) below the zygomatic arch.

          5. Has received in the past 2 weeks prescription facial wrinkle therapies (e.g.,
             RENOVA®), topical steroids, skin irritating topical preparations, or pigmenting agents
             (self-tanning agents) below the zygomatic arch.

          6. Has received in the past 2 months or plans to receive during the study
             immunosuppressive medications or systemic steroids (intranasal / inhaled steroids
             acceptable).

          7. Has an acute inflammatory process or infection, or history of chronic or recurrent
             infection or inflammation with the potential to interfere with the study results or
             increase the risk of adverse events.

          8. Has a known bleeding disorder or is using medication that reduces blood coagulation,
             (e.g. aspirin, non-steroidal anti-inflammatory drugs, or warfarin) which may increase
             the risk of bleeding during the treatment session.

          9. Has a known history of severe allergies manifested by a history of anaphylaxis; or
             history or presence of multiple severe allergies.

         10. Has known allergy or hypersensitivity to hyaluronic acid preparations, gram positive
             bacterial proteins or Belotero® or Belotero® derivative.

         11. Has a known history of hyper- or hypo-pigmentation in the nasolabial folds, keloid
             formation, or hypertrophic scarring.

         12. Is a female of childbearing potential (e.g. not post-menopausal for at least one year
             or has not had a hysterectomy or tubal ligation) and is pregnant, lactating or plans
             to become pregnant during the study or is not using medically effective birth control.

         13. Has any other medical condition with the potential to interfere with the study or
             increase the risk of adverse events.

         14. Is enrolled or plans to enroll in a competitive or interfering study.

         15. Is an employee or direct relative of an employee of the investigational site or study
             sponsor.

         16. All Fitzpatrick skin types are eligible for study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glen Dale</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montclair</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>White Plains</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2012</study_first_submitted>
  <study_first_submitted_qc>July 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2012</study_first_posted>
  <results_first_submitted>April 2, 2014</results_first_submitted>
  <results_first_submitted_qc>July 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 4, 2014</results_first_posted>
  <last_update_submitted>July 3, 2014</last_update_submitted>
  <last_update_submitted_qc>July 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Belotero®: Hyaluronic Acid Dermal Filler</title>
          <description>Belotero®: Hyaluronic acid dermal filler</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="117"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="113"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The number of participants included in the analysis was per protocol. There were no imputation techniques used in the safety study.</population>
      <group_list>
        <group group_id="B1">
          <title>Belotero®: Hyaluronic Acid Dermal Filler</title>
          <description>Belotero®: Hyaluronic acid dermal filler</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="117"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.04" spread="9.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Severe Common Adverse Events</title>
        <description>The purpose of this study was to determine if the rate of “Severe” common adverse events after re-treatment with Belotero Balance differs from the combined rates reported in the Belotero® Balance IDE clinical trial and Belotero® Balance Fitzpatrick Skin Type IV-VI Study (Pre-Approval Studies).“Common” is defined as pre-specified adverse events occurring in &gt;= 5% of study subjects. These averse events are: bruising, itching, pain, redness, swelling, discoloration, nodule, and induration.</description>
        <time_frame>1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Belotero</title>
            <description>Belotero®: Hyaluronic acid dermal filler</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Severe Common Adverse Events</title>
          <description>The purpose of this study was to determine if the rate of “Severe” common adverse events after re-treatment with Belotero Balance differs from the combined rates reported in the Belotero® Balance IDE clinical trial and Belotero® Balance Fitzpatrick Skin Type IV-VI Study (Pre-Approval Studies).“Common” is defined as pre-specified adverse events occurring in &gt;= 5% of study subjects. These averse events are: bruising, itching, pain, redness, swelling, discoloration, nodule, and induration.</description>
          <units>percentage of 'severe' common AEs</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" lower_limit="3.5" upper_limit="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The analysis was performed by comparing the proportion of subjects with severe common adverse events in the post-market study to that occurred in the pre-market studies. It was pre-specified in the protocol that the proportion of subjects with severe common adverse events in the pre-market studies was 22%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.025</p_value>
            <p_value_desc>Ho (null): Ps &gt;= 22% versus Ha (alternate): Ps &lt; 22% where Ps is the proportion of subjects with common severe adverse events in the post-approval study. Ho is rejected if upper limit of the 95% CI of Ps &lt; 22% and the one-sided p-value &lt;= 0.025.</p_value_desc>
            <method>One sided binomial distribution</method>
            <method_desc>The upper limit of the 95% two-sided CI for a proportion is equivalent to the 97.5% one-sided CI for that proportion for normal approximations.</method_desc>
            <param_type>One-sided binomial</param_type>
            <param_value>8.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.5</ci_lower_limit>
            <ci_upper_limit>13.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The purpose of this study was to determine the rate of &quot;Severe&quot; common adverse events after re-treatment with Belotero Balance differs from the combined rates reported in Belotero Balance IDE and Belotero Balance Fitzpatrick Skin Type IV-VI Study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Belotero®: Hyaluronic Acid Dermal Filler</title>
          <description>Belotero®: Hyaluronic acid dermal filler</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Needle Jam</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Itching</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Discoloration</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Nodule</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Induration</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>No manuscripts may be submitted for publication without prior review by the Sponsor. Investigator agrees to accommodate requests by Sponsor to protect proprietary rights/interests. Sponsor will be given full credit/acknowledgment for support provided for any publication resulting from this research. Investigator shall grant to the Sponsor an irrevocable royalty free, non-exclusive right to reproduce, translate, use all such copyrighted material arising from publications from study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Merz Pharmaceuticals North America</name_or_title>
      <organization>Merz Pharmaceuticals North America</organization>
      <phone>800-334-0514</phone>
      <email>clinicaltrials@merzusa.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

